BanwellBKruppLKennedyJ, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 2007;6:773-781. doi:10.1016/S1474-4422(07)70196-5
3.
AlroughaniRBoykoA.Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18:27. doi:10.1186/s12883-018-1026-3
4.
ChitnisT.Pediatric central nervous system demyelinating diseases. Continuum (Minneap Minn). 2019;25:793-814. doi:10.1212/CON.0000000000000730
5.
DeivaKAbsoudMHemingwayC, et al. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology. 2015;84:341-349. doi:10.1212/WNL.0000000000001179
6.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162-173. doi:10.1016/S1474-4422(17)30470-2
7.
KruppLBTardieuMAmatoMP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19:1261-1267.
8.
WongYMde MolCLvan der Vuurst de VriesVD, et al. Real-world validation of the 2017 McDonald criteria for pediatric MS. Neurol Neuroimmunol Neuroinflamm. 2019;6:e528.
9.
FaddaGBrownRALongoniG, et al. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health. 2018;2:191-204.
10.
HacohenYBrownleeWMankadK, et al. Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children a real-life cohort. Mult Scler. 2020;26:1372-1380.
11.
HardingKWilliamsOWillisM, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536-541. doi:10.1001/jamaneurol.2018.4905
